Roche Tecentriq FDA approval expands treatment for stage III dMMR colon cancer
FDA approval moves Tecentriq into adjuvant stage III dMMR colon cancer after ATOMIC showed a 50% reduction in recurrence or death risk.
Pharma & Biotech
Features & Analysis
How hyaluronidase is turning blockbuster antibody infusions into injections measured in minutes
Hyaluronidase temporarily clears a molecular barrier inside subcutaneous tissue, allowing large antibody doses to disperse and absorb from injection volumes that would otherwise be impractical.
Pharma & Biotech
Why Genentech’s Tecentriq Priority Review could change adjuvant colon cancer treatment
Find out how Genentech’s Tecentriq Priority Review could reshape adjuvant treatment for stage III dMMR/MSI-H colon cancer.
Medical Devices & Diagnostics
Genentech’s Tecentriq decision puts Natera’s Signatera at the centre of precision bladder cancer care
Bladder cancer treatment is becoming more selective. Tecentriq’s ctDNA-guided approval may redefine who gets adjuvant immunotherapy.